Business Context and Reporting Period
Company: Inspire Medical Systems, Inc. (INSR)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2025
Business Overview: Inspire is a medical technology company developing and commercializing the Inspire system, a neurostimulation therapy for moderate to severe obstructive sleep apnea (OSA). The company operates as a single segment, selling primarily to hospitals and ambulatory surgery centers in the U.S. and select international markets.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $224,501 | $203,191 | $642,904 | $563,086 |
| Gross Profit | $192,728 | $170,793 | $545,750 | $476,088 |
| Gross Margin | 85.8% | 84.1% | 84.9% | 84.5% |
| Operating Income | $9,644 | $14,318 | $4,843 | $4,199 |
| Net Income | $9,932 | $18,497 | $9,332 | $18,285 |
| Diluted EPS | $0.34 | $0.60 | $0.31 | $0.60 |
| Cash & Equivalents | $112,845 | $150,150 | As of Sept 30, 2025 | |
| Total Investments | $298,100 | $366,391 | As of Sept 30, 2025 | |
| Working Capital | $475,646 | $542,305 | Calculated (Current Assets - Current Liab) |
Liquidity: As of September 30, 2025, the company held $410.9 million in cash, cash equivalents, and available-for-sale debt securities. There is no long-term debt reported on the balance sheet.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 10.5% year-over-year (YoY) in Q3 2025 and 14.2% for the nine-month period. Growth was driven by increased market penetration and awareness, partially offset by surgeon capacity constraints and delays in therapy adoption pending the full rollout of the Inspire V system.
- Profitability Decline: Net income decreased 46.3% YoY in Q3 and 49.0% for the nine-month period. This decline was primarily due to a significant increase in Selling, General, and Administrative (SG&A) expenses, particularly advertising and compensation.
- Expense Increases: SG&A expenses rose 21.8% in Q3 and 19.2% for the nine months, driven by a $16.7 million increase in marketing costs (Q3) and higher headcount-related compensation. R&D expenses decreased slightly (7.2% in Q3) due to reduced ongoing development costs for next-generation products.
- Share Repurchases: The company repurchased $125.0 million of common stock during the first nine months of 2025, including $50.0 million in Q3 under a new $200 million authorization.
- Inventory Build: Inventory increased by $61.7 million to $141.8 million to support higher sales volumes and the launch of the Inspire V system.
Guidance, Outlook, and Risks
- Product Transition (Inspire V): The Inspire V system was fully launched in the U.S. in May 2025. Management anticipates that patients and physicians may delay therapy until Inspire V is available at their locations, and customers may destock existing Inspire IV inventory. This is expected to impact revenue through the remainder of 2025 and into early 2026.
- Competitive Landscape (GLP-1s): The company notes the growing use of GLP-1 drugs (e.g., tirzepatide) for OSA treatment. While management believes these drugs may help patients qualify for Inspire therapy by reducing BMI, there is a risk that some patients may achieve disease resolution without Inspire, potentially reducing demand.
- Legal Proceedings:
- Patent Litigation: Inspire sued Nyxoah SA in May 2025 for patent infringement regarding the Genio device. Nyxoah filed a countersuit in September 2025 alleging Inspire IV and V infringe Nyxoah patents.
- Government Investigation: The company is cooperating with a Department of Justice investigation regarding marketing and reimbursement practices under the False Claims Act.
- Outlook: Management expects SG&A and R&D expenses to increase in the remainder of 2025 due to expanded marketing, headcount growth, and development of the SleepSync platform.
Investor Verification Checklist
- Revenue Sustainability: Verify the extent of revenue impact from the Inspire IV to Inspire V transition and customer destocking patterns in Q4 2025.
- Expense Trajectory: Monitor the effectiveness of increased advertising spend ($36.4M in Q3) in driving future revenue growth relative to the rising SG&A burn rate.
- Legal Exposure: Track the status of the patent litigation with Nyxoah and the DOJ investigation to assess potential financial liabilities or operational restrictions.
- GLP-1 Impact: Assess clinical data and market feedback regarding the long-term impact of GLP-1 therapies on the addressable market for Inspire devices.
- Cash Position: Confirm the runway provided by the $410.9 million cash balance against the projected increase in operating expenses and capital expenditures for 2025.